Medication info
Pioglitazone Tablets (Pioglitazone Hydrochloride)

Pioglitazone Tablets (Pioglitazone Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Pioglitazone Hydrochloride›16.53mg / 1 tablet
Manufacturer / importer
Dongkook Pharmaceutical Co., Ltd.
Appearance
White to grayish-white, convex cylindrical tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 200703463 · Notified 2007.03.27 · Insurance code 653400290

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults · Children
Adult dose
This drug is administered orally once daily, regardless of meals. If glycemic control does not worsen in patients with diabetes, treatment should be continued for an appropriate period (at least 3 months) to assess changes in glycated hemoglobin. 1. Monotherapy In patients whose blood glucose is not adequately controlled by diet and exercise, this drug may be initiated as monotherapy with pioglitazone 15 mg once daily. If the initial dose of this drug does not provide sufficient efficacy, the dose may be increased to 30 mg once daily. 2. Combination therapy 1) Sulfonylurea: This drug may be administered in combination with a sulfonylurea; the initial dose is 15 mg once daily. When used in combination with this drug, the current sulfonylurea may be continued at the same dose and schedule. However, if the patient develops symptoms of hypoglycemia, the sulfonylurea dose should be reduced. 2) Metformin: This drug may be administered in combination with metformin; the initial dose is 15 mg once daily. When used in combination with this drug, the current metformin may be continued at the same dose and schedule. It is unlikely that the metformin dose will need to be adjusted because of hypoglycemic symptoms during combination therapy with this drug. 3) Insulin: This drug may be administered in combination with insulin; the dose is 15 mg once daily. The current insulin dose may be maintained when combination therapy with this drug is initiated. However, if a patient receiving this drug in combination with insulin develops symptoms of hypoglycemia or the plasma glucose concentration decreases to 100 mg/dL or below, the insulin dose may be reduced by 10 ~ 25 %. Subsequent dose adjustments should be individualized according to glycemic control. Maximum recommended dose For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Dose adjustment is not recommended in patients with renal impairment.
Child dose
Use is not recommended in children under 18 years of age because there is no experience with use in this age group.

Ingredients

Manufacturer
Dongkook Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Abnormal blood sugar control in patients with type 2 diabetes
  • inadequate blood sugar improvement
View approved original text

This medication is used to improve blood sugar control in patients with type 2 diabetes. It can be administered alone or in combination with other hypoglycemic agents to enhance glycemic control, in conjunction with dietary and exercise therapy. Particularly, if there is no improvement in blood sugar despite the use of other oral hypoglycemic agents, it can be administered in combination with sulfonylureas, metformin, or insulin. Additionally, nutritional counseling, weight loss, and exercise therapy are important not only for initial treatment but also for maintaining the effectiveness of drug therapy. This medication effectively improves blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

This drug is administered orally once daily, regardless of meals. If glycemic control does not worsen in patients with diabetes, treatment should be continued for an appropriate period (at least 3 months) to assess changes in glycated hemoglobin. 1. Monotherapy In patients whose blood glucose is not adequately controlled by diet and exercise, this drug may be initiated as monotherapy with pioglitazone 15 mg once daily. If the initial dose of this drug does not provide sufficient efficacy, the dose may be increased to 30 mg once daily. 2. Combination therapy 1) Sulfonylurea: This drug may be administered in combination with a sulfonylurea; the initial dose is 15 mg once daily. When used in combination with this drug, the current sulfonylurea may be continued at the same dose and schedule. However, if the patient develops symptoms of hypoglycemia, the sulfonylurea dose should be reduced. 2) Metformin: This drug may be administered in combination with metformin; the initial dose is 15 mg once daily. When used in combination with this drug, the current metformin may be continued at the same dose and schedule. It is unlikely that the metformin dose will need to be adjusted because of hypoglycemic symptoms during combination therapy with this drug. 3) Insulin: This drug may be administered in combination with insulin; the dose is 15 mg once daily. The current insulin dose may be maintained when combination therapy with this drug is initiated. However, if a patient receiving this drug in combination with insulin develops symptoms of hypoglycemia or the plasma glucose concentration decreases to 100 mg/dL or below, the insulin dose may be reduced by 10 ~ 25 %. Subsequent dose adjustments should be individualized according to glycemic control. Maximum recommended dose For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Dose adjustment is not recommended in patients with renal impairment.

Child dose

Use is not recommended in children under 18 years of age because there is no experience with use in this age group.

Precautions

This medication is used in the treatment of type 2 diabetes and aids the effect of insulin. This medication may burden the heart, and should not be used in patients with congestive heart failure or those with a history of heart failure. After starting treatment, close observation is required for sudden weight gain, shortness of breath, and leg swelling, which are symptoms of heart failure; if such symptoms occur, consult a physician immediately. Patients with heart failure or symptoms of heart failure should not take this medication. This medication may cause fluid retention, which could worsen heart failure; therefore, consult with a physician if symptoms of fluid retention or edema occur. Patients with bladder cancer or a history of bladder cancer should not take this medication, and if urinary symptoms or hematuria occur during treatment, notify medical staff immediately. This medication is not to be administered to patients with poor liver and kidney function, and if liver dysfunction is suspected, regular liver function tests are recommended. There is a risk of hypoglycemia when taken with other diabetes medications such as sulfonylureas or insulin, so caution is advised, and if symptoms of hypoglycemia appear, immediate action should be taken. During treatment with this medication, side effects such as edema, weight gain, headache, upper respiratory infection may occur; if any abnormal symptoms persist or worsen, inform a doctor. For premenopausal women, this medication may induce ovulation, so effective contraception should be used due to the possibility of pregnancy. Women who are pregnant or may become pregnant should not take this medication, and nursing mothers should consult medical personnel before taking it. Elderly patients, patients with poor nutritional status, and those with a history of cardiovascular disease should use this medication with caution. This medication should be taken once daily, and caution is advised to avoid taking a double dose the following day if a dose is missed. There may be drug interactions, so if you are taking other medications, be sure to inform your medical staff, especially if taking CYP2C8 inhibitors or inducers, as dosage adjustment may be necessary. In case of overdose, even if there are no specific symptoms, notify medical staff immediately for appropriate treatment. This medication has not been confirmed for safety and efficacy in children, so it is not used in this population.

Side effects

Congestive heart failure, excessive and rapid weight change, dyspnea, edema, fluid retention, edema, headache, sinusitis, myalgia, pharyngitis, abdominal distension, weight gain, hypoglycemia, upper respiratory infection, urinary tract infection, low back pain, dizziness, diarrhea, elevated serum creatine kinase, hypertension, heart failure, limb pain, chest pain, death due to cardiovascular factors, worsening of congestive heart failure, emergency room visits due to congestive heart failure, cardiovascular adverse events, increased blood sugar, elevated ALT/AST, loss of appetite, constipation, upper abdominal pain, chest pain, fatigue, weakness, indigestion, nausea, dyspnea, itching, chest discomfort, tremors, chills, gastrointestinal disease, abdominal pain, epigastric discomfort, paresthesia, muscle rigidity, head discomfort, increased liver enzymes, worsening of liver disease, hives, eczema, arthralgia, knee abnormalities, arm weakness, proteinuria, increased serum creatinine, anxiety, insomnia, drowsiness, simple herpes, blurred vision, orthostatic hypotension, palpitations, stroke, sexual dysfunction, myocardial infarction, weight gain, bladder cancer, macular edema, fracture

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to prevent contact with air. It is important to maintain storage temperatures between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

White to grayish-white, convex cylindrical tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.